Q2 FY2026 · ended Jun 30, 2026 · Revenue $63,104, +122.6% YoY · Filed Aug 13, 2026
Aspire Biopharma Holdings, Inc. (ASBP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $63,104 and a net loss of $1.3 million.
Revenue
$63,104
+122.6% vs prior quarter
Net income
$-1.27M
+36.0% vs year-ago quarter
Operating cash flow
$-2.12M
-85.5% vs year-ago quarter
Free cash flow
—
EPS
$-1.22
+94.1% vs prior quarter
Dividend per share
None
Shares outstanding
1.40M
-97.2% vs year-ago quarter
Net cash
—
Operating margin
-4244.1%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ASBP (Nasdaq), ASBPW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Estero, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1847345
- Former names
- Aspire Biopharma Holdings, Inc. (until Sep 9, 2026); PowerUp Acquisition Corp. (until Feb 19, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $63,104 | $28,353 | $4,261 | $1,941 | — |
| Operating income | -$2.7M | -$1.6M | -$1.8M | -$1.1M | — |
| Net income | -$1.3M | -$3.2M | -$4.7M | -$1.9M | -$2.0M |
| Diluted EPS | -$1.22 | -$20.57 | $0.04 | -$0.04 | — |
| Operating cash flow | -$2.1M | -$3.0M | -$927,841 | -$1.1M | -$1.1M |
| Total assets | $13.5M | $7.1M | $1.3M | $2.4M | $989,422 |
| Total liabilities | $1.8M | $3.2M | $7.7M | $13.9M | $10.6M |
| Stockholders' equity | $11.8M | $3.9M | -$6.4M | -$11.5M | -$9.6M |
| Cash and investments | $12.2M | $5.9M | $1.0M | $1.9M | $206,233 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K/A |
Amended current report
Material agreement
|
Oct 20, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 29, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Sep 9, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 19, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 228 Aspire Biopharma Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.